Symbols

ADAG

Adagene·NASDAQ

--(--)

Market Open: --

--(--)

Pre-Market: --

Signals Analysis

Bullish signal 1

Bearish signal 0

Consensus Rating "Strong Buy"

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About ADAG

Adagene Inc.

A clinical-stage biotechnology company that develops antibody therapeutics for the treatment of cancer

Industry

Pharmaceutical

Established Date

02/25/2011

Listing Date

02/09/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

138

Fiscal Year Ends

12-31

Website

www.adagene.com

Security Type

Depository Receipts (Ordinary Shares)

Office address

4F, Building C14, No. 218, Xinghu Street, Suzhou Industrial Park, Suzhou, Jiangsu Province, 215123, People's Republic of China

Business

Research, development and production of cancer monoclonal antibody drugs

Introduction

Tianyan Pharmaceutical is a limited liability company incorporated in the Cayman Islands on February 25, 2011. They are a private, global, clinical-stage immunotherapy company that redefines antibody discovery and design, opening up new frontiers for cancer treatment. Driven by a powerful platform that combines computational biology and artificial intelligence, they have created new antibodies that overcome safety issues. Improve efficacy and bring hope to more cancer patients. Their discovery engine, Dynamic Precision Library, is pushing Adagene's array of programs into potentially best-in-class or best-in-class programs. They have established strategic partnerships with a number of well-known global companies. These partnerships apply their technologies to the frontiers of science, including safer precision-guided antibody-drug conjugates, transformational antibody designs and advanced CAR constructs to address significant unmet needs. Founded and led by world-class leaders in antibody discovery and engineering, they have raised more than $150 million from well-known investors. In areas where other treatments have had little or no success, Adagene is well positioned to meet unmet needs.

Company Financials

EPS

ADAG has released its 2024 Q4 earnings. EPS was reported at -0.33, versus the expected -0.33, meeting expectations. The chart below visualizes how ADAG has performed over recent quarters, highlighting trends in earnings surprises.